New Vaccine Prevents Severe RSV Illness
-
By
December 13, 2024
-
2 min
-
1
RSV-preF vaccine was 91% effective at preventing RSV-related hospitalizations and emergency department visits in adults aged 60 years and older.
-
2
The study analyzed data from 7,047 lower respiratory tract disease encounters.
-
3
Vaccinating approximately 250 persons could prevent one RSV-related emergency department visit or hospitalization in the first season after vaccination.
-
4
57.4% of participants were aged 75 or older.
-
5
The investigation employed salvaged respiratory specimens for enhanced testing methods, increasing the study size.
-
A large-scale study conducted at Kaiser Permanente Southern California found that the respiratory syncytial virus prefusion F vaccine was 91% effective at preventing RSV-related hospitalizations and emergency department visits among adults aged 60 years and older. The retrospective case-control study analyzed data from 7,047 lower respiratory tract disease encounters, and the researchers found an adjusted vaccine effectiveness of 91%. Vaccinating approximately 250 persons could prevent one RSV-related emergency department visit or hospitalization in the first season after vaccination. The study represented the first major real-world effectiveness analysis of RSVpreF vaccination since its licensure in 2023.
-
1
RSV-preF vaccine was 91% effective at preventing RSV-related hospitalizations and emergency department visits in adults aged 60 years and older.
-
2
The study analyzed data from 7,047 lower respiratory tract disease encounters.
-
3
Vaccinating approximately 250 persons could prevent one RSV-related emergency department visit or hospitalization in the first season after vaccination.
-
4
57.4% of participants were aged 75 or older.
-
5
The investigation employed salvaged respiratory specimens for enhanced testing methods, increasing the study size.
Listen Tab content